Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics, Inc. (NASDAQ:AKRO) has announced the publication of results from the HARMONY Phase 2b trial in nonalcoholic steatohepatitis (NASH) in The Lancet Gastroenterology & Hepatology. The company is a clinical-stage company developing treatments for patients with serious metabolic disease.
October 04, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akero Therapeutics has published the results of its HARMONY Phase 2b trial in NASH, which could potentially impact the company's stock positively if the results are promising.
The publication of positive clinical trial results often leads to an increase in the company's stock price as it indicates progress in the company's pipeline. However, the exact impact will depend on the details of the results, which are not provided in the news.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100